证券代码：838810 证券简称：春光药装 公告编号：2024-031 辽宁春光制药装备股份有限公司 关于收到北京证券交易所对公司的问询函公告 4.结合上述事项说明公司会计核算、财务制度和内部控制是否存在重大缺陷 及拟采取的改善措施，是否能够保证公司财务数据真实、准确、完整，前期会 计处理是否审慎，是否存在调节利润的情形； 5.说明是否按照《北京证券交易所股票上市规则（试行）》的相关要求，对 业绩快报、业绩预告相关财务数据进行及时修正并披露； 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 辽宁春光制药装备股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日 收到北京证券交易所上市公司管理部下发的《关于对辽宁春光制药装备股份有限 公司的问询函》（问询函【2024】第 011 号）（以下简称"《问询函》"），现将《问 询函》内容公告如下： 辽宁春光制药装备股份有限公司（春光药装）董事会、中信建投证券股份 有限公司： 2024 年 4 月 25 日，你公司披露《业绩快报修正公告》《业绩预告修正 ...

关于对辽宁春光制药装备股份有限公司 的问询函 问询函【2024】第 011 号 辽宁春光制药装备股份有限公司（春光药装）董事会、中信 建投证券股份有限公司： 2024 年 4 月 25 日，你公司披露《业绩快报修正公告》 《业绩预告修正公告》，对业绩快报、业绩预告中的财务数 据进行修正。归属于上市公司股东的扣除非经常性损益的净 利润由 837.26 万元修正为 516.79 万元，调整比例为 38.28%。 你公司解释修正原因一是对应收账款及合同资产的预期信 用损失测试进行复核，增加计提信用及资产减值损失；二是 调整三年以上预付账款至其他应收款，并全额计提坏账准 备；三是对向客户销售及向该客户关联方采购业务进行了合 同合并，并依据合同开始日的公允价值，调减了对该客户的 营业收入。 请你公司： 1. 结合公司应收账款及合同资产的详细情况，说明预期 信用损失测试的具体过程及依据，增加计提信用及资产减值 损失对公司业绩的影响金额； 2. 结合预付账款产生背景及交易对手方具体情况，说明 调整至其他应收款并全额计提坏账准备的原因，对手方是否 与公司存在关联关系，公司已采取或拟采取的催收措施； 3. 结合向客户销售及向该 ...

Financial Forecast Revision - The company revised its 2023 net profit forecast to approximately CNY 14,485,200, a decrease of 64.68% compared to the previous year's CNY 41,013,200[4] - The revision was due to increased provisions for expected credit losses on accounts receivable and contract assets, as well as adjustments to prepaid accounts over three years[5] - The performance period for the forecast is from January 1, 2023, to December 31, 2023[3] Risk Warning and Disclosure - The company has issued a risk warning regarding the financial data, advising investors to refer to the detailed annual report for accurate figures[8] - The board of directors has apologized for any inconvenience caused by the forecast revision and committed to improving information disclosure quality in the future[7]

Corporate Recognition and Achievements - In 2023, the company was awarded the title of "Integrity Enterprise" by Jinzhou Credit Association and Jinzhou Small and Medium Enterprises Federation[4] - The company participated in the 25th Annual Golden Bull Award Ceremony in November 2023, winning the "Golden Bull Small Giant Award"[4] - The company was recognized as one of the first "Explosive Products" enterprises in Jinzhou in May 2023[6] Subsidiaries and Business Structure - The company established a wholly-owned subsidiary, Liaoning Jinwang Equipment Installation Engineering Service Co., Ltd., in September 2023[4] - The company included three subsidiaries in the consolidated financial statements, with two newly established subsidiaries in 2023, holding 100% and 60% stakes respectively[114] Financial Performance - The company's operating revenue for 2023 was ¥165,071,927.79, a decrease of 23.61% compared to ¥216,082,516.98 in 2022[27] - The net profit attributable to shareholders for 2023 was ¥14,485,196.39, down 64.68% from ¥41,013,230.25 in 2022[27] - The gross profit margin for 2023 was 32.25%, significantly lower than 47.13% in 2022[27] - Total assets increased by 5.55% to ¥458,091,452.82 at the end of 2023, compared to ¥433,992,572.72 at the end of 2022[29] - Total liabilities rose by 15.08% to ¥174,968,345.64 at the end of 2023, up from ¥152,040,697.45 at the end of 2022[29] - The company's cash flow from operating activities decreased by 83.27% to ¥8,083,726.75 in 2023, compared to ¥48,321,113.32 in 2022[29] - The weighted average return on equity (ROE) based on net profit attributable to shareholders was 5.13% in 2023, down from 34.87% in 2022[27] - The basic earnings per share for 2023 was ¥0.21, a decline of 72.93% from ¥0.78 in 2022[27] Research and Development - The company holds a total of 41 authorized patents, including 12 invention patents, reflecting strong technological innovation capabilities[38] - The company has established a research and innovation mechanism focusing on customer and market needs, enhancing its R&D capabilities through partnerships with universities and research institutions[38] - The company is actively pursuing new technologies and product development, although specific new products were not detailed in the report[88] - R&D expenditure for the current period amounted to ¥9,209,998.60, representing an increase of 3.37% compared to the previous period's ¥8,909,482.96[94] - The increase in R&D costs was driven by a 76.71% rise in material costs due to a shift from collaborative to independent R&D projects[95] Market and Industry Trends - The packaging equipment industry is experiencing growth driven by digital transformation and smart manufacturing, increasing demand for intelligent equipment and production lines[49] - The global packaging industry market size grew from $843.8 billion in 2015 to $914.7 billion in 2019, then decreased to $859.9 billion in 2020 due to economic downturn, with an expected growth to $1.13 trillion by 2030[50] - The global packaging equipment market was valued at $43.6 billion in 2020 and is projected to reach $54.9 billion by 2027, with a CAGR of 3.3%[50] Client Relationships and Sales - Major clients accounted for 39.96% of total sales, with the largest client, Yili, contributing CNY 27,316,911.57, representing 16.55% of total sales[76] - The company has established stable partnerships with leading firms in the pharmaceutical and food sectors, enhancing its market reputation and brand influence[54] Financial Management and Investments - The company has secured loans from various banks, including a 160,000,000.00 CNY loan from Dian Guan Ke Construction Bank, with a repayment period extending to 2031[151] - The company has ongoing investments in the intelligent automation equipment production base, with total actual investment reaching CNY 121,208,930.37 by the end of the reporting period[83] - The company reported a total of 428,400.00 yuan in litigation as a defendant, representing 0.15% of the total net assets at the end of the reporting period[132] Governance and Compliance - The company has established new corporate governance systems during the year, enhancing its internal control mechanisms[194] - The governance mechanism effectively protects the rights of all shareholders, ensuring equal rights and participation in decision-making processes[197] - Major decisions such as external guarantees, investments, and related transactions were conducted in accordance with internal control procedures and legal regulations[200] Employee Management and Development - The company has implemented a competitive salary policy and provides various employee benefits, including health check-ups and commercial insurance[188] - The number of management personnel increased from 23 to 39, with a net addition of 16 personnel during the reporting period[186] - The company has a stable core technical team, with R&D capabilities that are improving, ensuring that their packaging equipment meets or exceeds the functionality of similar imported equipment[125]

Financial Performance - Revenue for Q1 2024 was CNY 10,747,829.83, a significant decrease of 78.94% from CNY 51,045,814.36 in Q1 2023[12] - Net profit attributable to shareholders was a loss of CNY 3,342,147.31, down 143.49% from a profit of CNY 7,684,095.67 in the same period last year[12] - Operating profit for the same period was -4.04 million yuan, down 145.53% year-on-year, attributed to changes in market demand leading to decreased product revenue[15] - The net profit for the first quarter of 2024 was -3.50 million yuan, a decrease of 145.57% year-on-year, primarily due to a decline in revenue and gross margin[15] - The company's total comprehensive income for Q1 2024 was -¥4,077,480.89, compared to ¥7,982,611.80 in Q1 2023, highlighting a drastic shift in overall financial performance[52] Cash Flow - Operating cash flow for the quarter was a negative CNY 11,430,013.86, representing a decline of 305.55% compared to a negative CNY 2,818,387.26 in Q1 2023[12] - The net cash flow from operating activities was -12,258,376.66, compared to -2,433,742.72 in the previous year, indicating a significant decline[56] - Cash inflow from financing activities amounted to 12,589,419.41, while cash outflow was 568,649.24, resulting in a net cash flow of 12,020,770.17, compared to -1,620,487.88 previously[56] - The company reported a significant decrease in cash and cash equivalents, with a net decrease of 2,604,906.49 compared to -51,893,336.39 last year[56] Assets and Liabilities - Total assets increased by 3.66% to CNY 474,853,107.79 as of March 31, 2024, compared to CNY 458,091,452.82 at the end of 2023[12] - Total liabilities increased to CNY 195,129,520.70 from CNY 174,968,345.64, reflecting a rise of approximately 11.5%[45] - Current assets increased to CNY 290,555,082.54 as of March 31, 2024, up from CNY 273,910,270.25 on December 31, 2023, representing a growth of approximately 6.4%[43] - The company's total assets reached CNY 474,853,107.79, up from CNY 458,091,452.82, indicating a growth of about 3.5%[45] Shareholder Information - The total number of ordinary shares was 68.5 million, with 37.80% being unrestricted shares and 62.20% being restricted shares[19] - Major shareholders include Bi Chunguang with 26.72% and Bianjing with 19.85% of the shares[20] - There were no pledged or judicially frozen shares among the major shareholders[22] Research and Development - Research and development expenses increased by 46.57% to CNY 1,999,529.25, reflecting the company's commitment to enhancing R&D efforts[14] - Research and development expenses for Q1 2024 were CNY 1,999,529.25, compared to CNY 1,364,229.54 in Q1 2023, representing an increase of approximately 46.5%[49] Debt and Financing - The company's debt-to-asset ratio rose to 41.09% from 38.20% year-over-year, indicating increased leverage[12] - Short-term borrowings rose by 44.38% to CNY 40,955,897.22, driven by the need for working capital[14] - The company maintained its long-term borrowings at CNY 26,400,000.00, unchanged from the previous year[48] Other Financial Metrics - The weighted average return on equity dropped to -1.19% from 7.61% in the previous year, indicating a decline in profitability[12] - The company reported a credit impairment loss of CNY -417,522.35 in Q1 2024, worsening from CNY -333,763.53 in Q1 2023[50] - Total operating costs for Q1 2024 amounted to CNY 17,378,642.04, compared to CNY 42,403,116.82 in Q1 2023, indicating a decrease of about 58.9%[49]

证券代码：838810 证券简称：春光药装 公告编号：2024-014 辽宁春光制药装备股份有限公司 第三届监事会第十四次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 本次会议的召集、召开符合《公司法》《公司章程》《监事会议事规则》的相 关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 3.回避表决情况 本议案不涉及关联交易，无需回避表决。 本议案尚需提交股东大会审议。 （二）审议通过《关于 2023 年年度报告及摘要的议案》 1.议案内容： 二、议案审议情况 （一）审议通过《关于 2023 年度监事会工作报告的议案》 1.议案内容： 公司监事会对 2023 年度工作运营情况、监事会工作情况进行了总结，形成 了 2023 年度监事会工作报告。 1.会议召开时间：2024 年 4 月 23 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 4.发出监事会会议通知的时间和方式：2024 年 4 月 10 日 ...

证券代码：838810 证券简称：春光药装 公告编号：2024-017 辽宁春光制药装备股份有限公司 2023 年年度独立董事述职报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 我作为辽宁春光制药装备股份有限公司（以下简称"公司"）的独立董事，2023 年度，严格按照《公司法》《证券法》《北京证券交易所股票上市规则（试行）》 《北京证券交易所上市公司持续监管指引第 1 号——独立董事》等有关法律、法 规及《公司章程》《独立董事工作制度》的规定和要求，本着对全体股东负责的 态度，认真履行独立董事职责和义务，谨慎、认真、勤勉地行使公司所赋予的各 项权利，充分发挥独立董事作用。对公司重大事项发表客观、审慎、公正的事前 认可或独立意见，积极维护公司整体利益和全体股东特别是中小股东的合法权益。 现将 2023 年度履行独立董事职责的工作情况汇报如下： 一、独立董事的基本情况 张丽女士，1977 年 9 月出生，中国国籍，无境外永久居留权，大专学历， 中国注册会计师。2000 年 7 月至 2008 年 9 ...

证券代码：838810 证券简称：春光药装 公告编号：2024-025 辽宁春光制药装备股份有限公司 审计委员会对会计师事务所履行监督职责情况的报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》《公司章程》等规定和要 求，董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将审计委 员会对会计师事务所履行监督职责的情况汇报如下： 一、会计师事务所基本情况 1、基本情况 机构名称：大华会计师事务所（特殊普通合伙） 成立日期：2012 年 2 月 9 日 组织形式：特殊普通合伙 注册地址：北京市海淀区西四环中路 16 号院 7 号楼 1101 首席合伙人：梁春 2023 年度末合伙人数量：270 人 2023 年度末注册会计师人数：1,471 人 2023 年度末签署过证券服务业务审计报告的注册会计师人数：1141 人 2022 年收入总额（经审计）：332,731.85 万元 ...

证券代码：838810 证券简称：春光药装 公告编号：2024-027 辽宁春光制药装备股份有限公司 2023 年度募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 （二）募集资金使用情况 截至 2023 年 12 月 31 日，公司对募集资金项目累计投入 121,208,930.37 元， 其中 2023 年使用募集资金 87,073,747.15。截至 2023 年 12 月 31 日，募集资金账 户余额为人民币 716,510.72 元。 募集资金使用情况如下： 单位：元 | 募集资金净额 | | 143,496,286.79 | | --- | --- | --- | | 加：2022 | 年募集资金及现金管理利息收入 | 9,166.39 | | 减：2022 | | | 年支付审计费、律师费等发行费用税费 | | 152,830.19 | | --- | --- | --- | --- | --- | --- | | 减：2022 | 年手续费 | | | ...

证券代码：838810 证券简称：春光药装 公告编号：2024-024 机构名称：大华会计师事务所（特殊普通合伙） 成立日期：2012 年 2 月 9 日 组织形式：特殊普通合伙 注册地址：北京市海淀区西四环中路 16 号院 7 号楼 1101 首席合伙人：梁春 2023 年度末合伙人数量：270 人 2023 年度末注册会计师人数：1,471 人 2022 年收入总额（经审计）：332,731.85 万元 2022 年审计业务收入（经审计）：307,355.10 万元 辽宁春光制药装备股份有限公司 会计师事务所履职情况评估报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 辽宁春光制药装备股份有限公司（以下简称"公司"）聘请大华会计师事务 所（特殊普通合伙）（以下简称"大华"）作为公司 2023 年年度审计机构。根据 财政部及证监会颁布的《国有企业、上市公司选聘会计师事务所管理办法》《关 于上市做好选聘会计师事务所工作的提醒》等法律法规的要求，公司对大华在近 一年审计中的履职情况进行了评估，具体情况 ...